Health TrialsbyHealthPanel

Purinergic Signaling and the Postmenopausal Heart

ConditionsDiastolic Heart FailureHeart Failure With Preserved Ejection Fraction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-88
SponsorBeth Israel Deaconess Medical Center

About this trial

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients undergoing cardiac surgery under cardiopulmonary bypass.

Disqualifiers

Refusal to participate

Emergency surgery

Pre-existing heart block

Preexisting atrial fibrillation

Trial population

Patients presenting for elective cardiac surgery. Patients will be enrolled and consented during hospital admission for surgery.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Gender

    Other intervention

    Differences between men and women will be observed

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: Men1 intervention
Group B: Women1 intervention

Trial outcomes

Primary outcomes

1

Comparative quantification of expression of CD39 and adenosinergic receptors

Expression of CD39, ADORA2A and ADORA2B in cardiac tissue measured using Western blotting

Time frame
6 months
2

Comparative quantification of expression of PGC-1 alpha, mitochondrial markers

Expression of PGC-1 alpha, AMPK and mitochondrial markers using Western blot

Time frame
6 months
3

Comparative quantification of expression of angiogenic markers

Expression of angiogenic markers (PDGF, VEGF, Angiostatin)

Time frame
6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beth Israel Deaconess Medical Center

Lead sponsor

Source ClinicalTrials.gov
Apply now